(Press-News.org) Boston, MA — A newly discovered genetic variant may increase the risk of heart disease in people with type 2 diabetes by more than a third, according to a study led by researchers at Harvard School of Public Health (HSPH) and Joslin Diabetes Center. It is the first genome-wide association study (GWAS) to identify a novel genetic variant associated with coronary heart disease (CHD) in people with type 2 diabetes, who have a two- to four-fold higher risk of heart disease compared with those without diabetes. The finding could lead to new interventions aimed at preventing or treating CHD among patients with type 2 diabetes.
"This is a very intriguing finding because this variant was not found in previous genome-wide association studies in the general population," said lead author Lu Qi, assistant professor in the HSPH Department of Nutrition and assistant professor at the Channing Division of Network Medicine, Brigham and Women's Hospital. "This means that the genetic risk factors for cardiovascular disease may be different among those with and without diabetes."
"The identification of this genetic variant opens up the possibility of developing treatments that are specifically aimed at breaking the links between diabetes and CHD," said co-lead author Alessandro Doria, associate professor in the Department of Epidemiology at HSPH and a researcher at Joslin Diabetes Center.
The study appears online August 27 and will appear in the August 28, 2013 issue of JAMA (Journal of the American Medical Association).
More than 370 million people worldwide have type 2 diabetes and CHD is the leading cause of death among diabetic patients. Overall CHD-related mortality has been declining in the United States and other industrialized countries over the past few decades. But CHD deaths that are diabetes-related are on the rise because of the increasing prevalence of the latter ailment. Although prior genome-wide studies have found many genetic variants for CHD in people in the general population, no such study had examined genetic determinants for CHD specifically in those with type 2 diabetes.
For their analysis, the researchers used data from several long-term studies: the Nurses' Health Study, the Health Professionals Follow-up Study, the Joslin Heart Study, and two Italian studies—the Gargano Heart Study and the Catanzaro Study. They looked at 4,188 diabetic patients, including 1,517 with CHD and 2,671 without CHD as a control group.
Testing more than 2.5 million genetic variants, the researchers found that a variant near the GLUL gene, a gene that encodes a key enzyme regulating the conversion of glutamic acid to glutamine, was consistently associated with a 36% increased risk of CHD in people with diabetes. There was no association between this variant and CHD risk in study participants without diabetes.
They also found that the variant may interfere with the expression of a gene that regulates blood levels of amino acids involved in insulin secretion and glucose metabolism—key functions that go awry in those with type 2 diabetes.
Since these amino acids are nutrients affected by food intake, it's possible that changes in diet may help reduce increased CHD risk among people with diabetes. The finding may also provide scientists with other targets for therapies to help prevent or treat CHD in diabetic patients.
###
Other HSPH and Channing researchers involved in the study included Eric Rimm, associate professor of epidemiology and nutrition; Frank Hu, professor of nutrition and epidemiology; and Qibin Qi, research fellow in the Department of Nutrition.
Funding for the study came from grants HL071981, DK091718, HL073168, DK046200 (Boston Obesity Nutrition Research Center), and DK36836 (Genetics Core of the Diabetes Research Center at Joslin Diabetes Center) from the National Institutes of Health, an American Heart Association Scientist Development Award (0730094N), a grant from the Italian Ministry of Health ('Ricerca Corrente 2011 e 2012'), and a grant from Fondazione Roma ('Sostegno alla ricerca scientifica biomedica 2008'). A portion of this work was conducted in a facility constructed with support from the National Institutes of Health Research Facilities Improvement Program (RR10600-01, CA62528-01, RR14514-01) from the National Center for Research Resources.
"Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in type 2 diabetes," Lu Qi, Qibin Qi, Sabrina Prudente, Christine Mendonca, Francesco Andreozzi, Natalia di Pietro, Mariella Sturma, Valeria Novelli, Gaia Chiara Mannino, Gloria Formoso, Ernest V. Gervino, Thomas H. Hauser, Jochen D. Muehlschlegel, Monika A. Niewczas, Andrzej S. Krolewski, Gianni Biolo, Assunta Pandolfi, Eric Rimm, Giorgio Sesti, Vincenzo Trischitta, Frank Hu, and Alessandro Doria, JAMA, online August 27, 2013
About Harvard School of Public Health
Harvard School of Public Health brings together dedicated experts from many disciplines to educate new generations of global health leaders and produce powerful ideas that improve the lives and health of people everywhere. As a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory and the classroom to people's lives—not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices. Each year, more than 400 faculty members at HSPH teach 1,000-plus full-time students from around the world and train thousands more through online and executive education courses. Founded in 1913 as the Harvard-MIT School of Health Officers, the School is recognized as America's first professional training program in public health. For more information, visit http://www.hsph.harvard.edu.
About Joslin Diabetes Center
Joslin Diabetes Center, located in Boston, Massachusetts, is the world's largest diabetes research and clinical care organization. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School.
Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org.
About Joslin Research
Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30 plus faculty level investigators, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit http://www.joslinresearch.org.
Genetic variant identified that may increase heart disease risk among people with type 2 diabetes
2013-08-28
ELSE PRESS RELEASES FROM THIS DATE:
Zealous imaging fuelling unnecessary and harmful treatment of low risk thyroid cancers
2013-08-28
New technologies such as ultrasound, CT and MRI scanning can detect thyroid nodules as small as 2mm – many of these small nodules are papillary thyroid cancers.
In the US, cases have tripled in the past 30 years - from 3.6 per 100,000 in 1973 to 11.6 per 100,000 in 2009 – making it one of the fastest growing diagnoses. Yet the death rate from papillary thyroid cancer has remained stable.
This expanding gap between incidence of thyroid cancer and deaths suggests that low risk cancers are being overdiagnosed and overtreated, argue Dr Juan Brito and colleagues at the ...
The extraordinary evolution of REVs
2013-08-28
A new study by Anna Maria Niewiadomska and Robert Gifford, of The Aaron Diamond AIDS Research Center, New York, reveals that reticuloendotheliosis viruses (REVs), which originated in mammals, spread to birds as a result of medical intervention. Their findings will be published August 27 in the open access journal PLOS Biology.
"We became intrigued by these viruses", says Gifford, "…because their distribution in nature suggests something very unusual has occurred during their evolution."
The reticuloendotheliosis viruses (REVs) are retroviruses that were first identified ...
Size of personal space is affected by anxiety
2013-08-28
The space surrounding the body (known by scientists as 'peripersonal space'), which has previously been thought of as having a gradual boundary, has been given physical limits by new research into the relationship between anxiety and personal space.
New findings have allowed scientists to define the limit of the 'peripersonal space' surrounding the face as 20-40cm away. The study is published today in The Journal of Neuroscience.
As well as having numerical limits the specific distance was found to vary between individuals. Those with anxiety traits were found to have ...
Combination drug regimen may benefit patients with hepatitis C
2013-08-28
Treatment of chronic hepatitis C virus (HCV) genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA.
"Chronic infection with hepatitis C virus is a major cause of chronic liver disease, end-stage liver disease, hepatocellular cancer and remains the leading indication for liver transplants in western countries. The HCV epidemic in the United States is centered in large urban ...
Study examines relationship of a commercial ACO contract with medical spending
2013-08-28
Payment incentives implemented with a commercial accountable care organization (ACO) initiative in Massachusetts –Blue Cross Blue Shield's Alternative Quality Contract (AQC) – were associated with lower spending for Medicare enrollees served by the provider groups participating in the AQC, findings that suggest that evaluations of ACO programs may need to consider the implications for other patient populations to assess their full clinical and economic benefits, according to a study in the August 28 issue of JAMA.
"In response to mounting pressures to deliver more cost-effective ...
Genetic variant associated with increased CHD risk in individuals with type 2 diabetes
2013-08-28
Researchers have identified a previously unknown genetic locus (the place a gene occupies on a chromosome) significantly associated with increased coronary heart disease risk among patients with type 2 diabetes, but the association was not found in individuals without diabetes, according to a study in the August 28 issue of JAMA. The variant is functionally related to glutamic acid metabolism, suggesting a mechanistic link.
"The prevalence of type 2 diabetes has been steadily increasing in the United States and other countries, with the total number of affected people ...
X-ray of ducts during gallbladder surgery not linked with reduction in risk of common duct injury
2013-08-28
In an analysis of a procedure used to help prevent common duct injury during gallbladder removal surgery, use of intraoperative cholangiography (radiologic examination of the ducts during gallbladder surgery) was not associated with a reduced risk of common duct injury, according to a study in the August 28 issue of JAMA.
"Biliary anatomy misidentification during cholecystectomy [gallbladder removal] can result in injury to the common hepatic duct or common bile duct. Common duct injuries cause significant short- and long-term morbidity including major operations, multiple ...
Gastroenteritis hospitalizations in adults reduced since start of infant rotavirus vaccination
2013-08-28
"Implementation of infant rotavirus vaccination in 2006 has substantially reduced the burden of severe gastroenteritis among U.S. children younger than 5 years," write Paul A. Gastanaduy, M.D., M.P.H., of the Centers for Disease Control and Prevention, Atlanta, and colleagues. "Whether indirect protection (due to reduced transmission of rotavirus) extends to adults remains unclear."
As reported in a Research Letter, the authors assessed patterns of gastroenteritis hospitalizations among children 5 years of age or older and among adults before and after implementation ...
Early diabetes interventions may also reduce heart disease risk
2013-08-28
Chevy Chase, MD—Two treatments that slow the development of diabetes also may protect people from heart disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Researchers examined the effect that making intensive lifestyle changes or taking the medication metformin had on cholesterol and triglyceride levels. The study, part of the National Institutes of Health's Diabetes Prevention Program, found that both treatments induced positive changes in the level of particles that carry cholesterol ...
Low inflammation may explain healthy metabolic status in some obese people
2013-08-28
Chevy Chase, MD—Reduced levels of inflammation may explain how some obese people are able to remain metabolically healthy, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Obesity generally is linked to a higher risk of diabetes and heart disease. Some people who are obese, however, do not develop high blood pressure and unfavorable cholesterol profiles – factors that increase the risk of metabolic diseases. This phenomenon is described as metabolically healthy obesity. Although estimates ...